Is Prime Medicine, Inc. (PRME) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.6% / 30% | 26.3% / 30% | 0.0% / 30% | 118.07% / 5% | ✗ NOT HALAL |
| DJIM | 5.6% / 33% | 26.3% / 33% | 0.0% / 33% | 118.07% / 5% | ✗ NOT HALAL |
| MSCI | 13.7% / 33% | 64.0% / 33% | 0.0% / 33% | 118.07% / 5% | ✗ NOT HALAL |
| S&P | 5.6% / 33% | 26.3% / 33% | 0.0% / 33% | 118.07% / 5% | ✗ NOT HALAL |
| FTSE | 13.7% / 33% | 64.0% / 33% | 0.0% / 50% | 118.07% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -5800.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -146.8% | |
| Return on Assets (ROA) | -40.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$163M |
| Free Cash Flow | -$167M |
| Total Debt | $116M |
| Debt-to-Equity | 96.3 |
| Current Ratio | 4.8 |
| Total Assets | $343M |
Price & Trading
| Last Close | $3.64 |
| 50-Day MA | $3.80 |
| 200-Day MA | $3.98 |
| Avg Volume | 3.0M |
| Beta | 2.6 |
|
52-Week Range
$1.11
| |
About Prime Medicine, Inc. (PRME)
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Prime Medicine, Inc. (PRME) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Prime Medicine, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Prime Medicine, Inc.'s debt ratio?
Prime Medicine, Inc.'s debt ratio is 5.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.7%.
What are Prime Medicine, Inc.'s key financial metrics?
Prime Medicine, Inc. has a market capitalization of $610M, and revenue of $5M. Return on equity stands at -146.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.